Journal
FEBS JOURNAL
Volume 288, Issue 7, Pages 2084-2102Publisher
WILEY
DOI: 10.1111/febs.15515
Keywords
immune libraries; naive libraries; nanobodies; single-domain antibodies; synthetic libraries
Categories
Funding
- Vrije Universiteit Brussel
- VIB
- EU
- IWT
- FWO
- Innoviris
Ask authors/readers for more resources
Nanobodies, a trademark of Ablynx, are single antigen-binding domains of heavy chain-only antibodies in Camelidae produced recombinantly for research and medical applications. Various methods are used for their generation, producing cost-effective Nbs with high affinity for their target antigens. Additionally, engineering technologies have been explored to broaden the application range of Nbs for potential advantages over other affinity reagents.
A nanobody (Nb) is a registered trademark of Ablynx, referring to the single antigen-binding domain of heavy chain-only antibodies (HCAbs) that are circulating in Camelidae. Nbs are produced recombinantly in micro-organisms and employed as research tools or for diagnostic and therapeutic applications. They were - and still are - also named single-domain antibodies (sdAbs) or variable domain of the heavy chain of HCAbs (VHH). A variety of methods are currently in use for the fast and efficient generation of target-specific Nbs. Such Nbs are produced at low cost and associate with high affinity to their cognate antigen. They are robust, strictly monomeric and easy to tailor into more complex entities to meet the requirements of their application. Here, we review the various sources and different strategies that have been developed to identify rapidly, target-specific Nbs. We further discuss a variety of engineering technologies that have been explored to broaden the application range of Nbs and summarise those applications where designed Nbs might offer a marked advantage over other affinity reagents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available